Drugs / XL309
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05932862 | Apr 2024 → Jan 2029 expected | neoplasm | Exelixis | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05932862 ↗ |
| Route | Oral | “XL309 will be administered orally per assigned schedule.” NCT05932862 ↗ |